HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

David A Proia Selected Research

STA 9090

12/2018Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors.
11/2018High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
1/2018Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD).
1/2017Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood.
12/2016Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.
4/2016Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
2/2016Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer.
12/2015Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibition.
6/2015The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
5/2015The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


David A Proia Research Topics

Disease

31Neoplasms (Cancer)
12/2018 - 03/2006
6Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/2016 - 12/2012
5Breast Neoplasms (Breast Cancer)
04/2016 - 03/2006
4Lung Neoplasms (Lung Cancer)
12/2016 - 12/2012
3Autosomal Dominant Polycystic Kidney (ADPKD)
01/2018 - 07/2013
3Cysts
01/2018 - 07/2013
3Colorectal Neoplasms (Colorectal Cancer)
12/2014 - 10/2013
2Prostatic Neoplasms (Prostate Cancer)
11/2018 - 01/2013
2Triple Negative Breast Neoplasms
04/2016 - 01/2014
2Melanoma (Melanoma, Malignant)
02/2014 - 01/2012
2Leukemia
04/2011 - 11/2010
1Hematologic Neoplasms (Hematological Malignancy)
01/2021
1Pancreatic Neoplasms (Pancreatic Cancer)
01/2017
1Adenocarcinoma
01/2017
1Lymphoma (Lymphomas)
01/2017
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
10/2016
1Sarcoma (Soft Tissue Sarcoma)
10/2016
1Osteosarcoma (Osteogenic Sarcoma)
10/2016
1Anaphylaxis (Anaphylactic Shock)
02/2016
1Hypersensitivity (Allergy)
02/2016
1Adenocarcinoma of Lung
05/2015
1Colonic Neoplasms (Colon Cancer)
12/2014
1Diarrhea
12/2014
1Fatigue
12/2014
1Urinary Bladder Neoplasms (Bladder Cancer)
07/2014
1Carcinogenesis
03/2014
1Inflammatory Breast Neoplasms
02/2014
1Neoplasm Metastasis (Metastasis)
01/2014
1Hemorrhage
01/2014
1Polycystic liver disease
01/2014
1Hepatomegaly
01/2014
1Cholestasis
01/2014
1Rectal Neoplasms (Rectal Cancer)
10/2013

Drug/Important Bio-Agent (IBA)

25STA 9090IBA
12/2018 - 11/2010
11Proteins (Proteins, Gene)FDA Link
01/2017 - 11/2010
10Heat-Shock Proteins (Heat-Shock Protein)IBA
12/2018 - 11/2010
9Pharmaceutical PreparationsIBA
01/2021 - 01/2012
7Molecular Chaperones (Chaperone, Molecular)IBA
07/2014 - 02/2012
4Irinotecan (Camptosar)FDA LinkGeneric
01/2017 - 11/2015
4STA-12-8666IBA
01/2017 - 11/2015
4Hormones (Hormone)IBA
01/2016 - 03/2006
3Biological ProductsIBA
12/2018 - 06/2015
3Paclitaxel (Taxol)FDA LinkGeneric
04/2016 - 12/2012
2Transcription Factors (Transcription Factor)IBA
01/2021 - 02/2014
2Oncogene Proteins (Oncogene Protein)IBA
01/2021 - 05/2014
2ProdrugsIBA
12/2018 - 08/2014
2Topoisomerase I InhibitorsIBA
10/2016 - 11/2015
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
02/2014 - 02/2014
2STA-2842IBA
01/2014 - 07/2013
1STA-1474IBA
12/2018
1Phenobarbital (Luminal)FDA Link
11/2018
1Proteasome Endopeptidase Complex (Proteasome)IBA
11/2018
1Deoxyglucose (2 Deoxy D glucose)IBA
01/2018
1TRPP Cation ChannelsIBA
01/2018
1EBV-encoded nuclear antigen 1IBA
01/2017
1Cytotoxins (Cytolysins)IBA
10/2016
1Glucocorticoid Receptors (Glucocorticoid Receptor)IBA
04/2016
1taxaneIBA
04/2016
1AntibodiesIBA
02/2016
1Monoclonal AntibodiesIBA
02/2016
1Immunoglobulin G (IgG)IBA
02/2016
1Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA
01/2016
1Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA
01/2016
1Transforming Growth Factors (Transforming Growth Factor)IBA
01/2016
1Proto-Oncogene Proteins c-sis (Platelet Derived Growth Factor B)IBA
12/2015
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
12/2015
1Cisplatin (Platino)FDA LinkGeneric
12/2015
1CytokinesIBA
12/2015
1Interleukin-6 (Interleukin 6)IBA
12/2015
1Immune Checkpoint InhibitorsIBA
06/2015
1Erlotinib Hydrochloride (CP 358,774)FDA Link
06/2015
1ErbB Receptors (EGF Receptor)IBA
06/2015
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
06/2015
1Antineoplastic Agents (Antineoplastics)IBA
06/2015
1Gefitinib (Iressa)FDA Link
06/2015
1CateninsIBA
05/2015
1Estrogen Receptor Modulators (Antiestrogen)IBA
12/2014
1Estrogen ReceptorsIBA
12/2014
1Aspartate Aminotransferases (Aspartate Transaminase)IBA
12/2014
1Alkaline PhosphataseIBA
12/2014
1Alanine Transaminase (SGPT)IBA
12/2014
1Capecitabine (Xeloda)FDA Link
08/2014
1Fluorouracil (Carac)FDA LinkGeneric
08/2014
1tyrosine receptor (receptor, tyrosine)IBA
02/2014
1TAK 733IBA
02/2014
1VemurafenibIBA
02/2014
1Lapatinib (GW572016)FDA Link
02/2014
1Proto-Oncogene Proteins B-rafIBA
02/2014
1Caspase 8 (Caspase-8)IBA
01/2014
11-dodecylpyridoxal (PLD)IBA
01/2014
1Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
10/2013
1Messenger RNA (mRNA)IBA
10/2013
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2013

Therapy/Procedure

15Therapeutics
11/2018 - 11/2010
6Drug Therapy (Chemotherapy)
01/2017 - 11/2010
1Castration
11/2018
1Immunomodulation
02/2016
1Radiotherapy
12/2015
1Immunotherapy
06/2015
1Aftercare (After-Treatment)
12/2014